{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T20:25:51Z","timestamp":1794255951267,"version":"4.9.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004271","name":"Sapienza University of Rome","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004271","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jacadv.2026.102790","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T09:22:26Z","timestamp":1778836946000},"page":"102790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["SGLT2 Inhibitors in Cardio-Oncology"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-4121","authenticated-orcid":false,"given":"Luigi","family":"Spadafora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Sarto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Simeone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1872-1757","authenticated-orcid":false,"given":"Erica","family":"Rocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8163-0527","authenticated-orcid":false,"given":"Salvatore","family":"Carbone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6516-0959","authenticated-orcid":false,"given":"Laura Adelaide","family":"Dalla Vecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Franco Enrico","family":"Pedretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Valenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Di Mario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Forte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Frati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1835-6128","authenticated-orcid":false,"given":"Antonio","family":"Abbate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0141-0127","authenticated-orcid":false,"given":"Michele","family":"Golino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Versaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Sabouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6103-8510","authenticated-orcid":false,"given":"Giuseppe","family":"Biondi Zoccai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastiano","family":"Sciarretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.jacadv.2026.102790_bib1","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102790_bib2","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s40256-024-00673-1","article-title":"SGLT2 inhibitors and how they work beyond the glucosuric effect. State of the art","volume":"24","author":"Aristizabal-Colorado","year":"2024","journal-title":"Am J Cardiovasc Drugs"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib3","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s00395-024-01059-9","article-title":"Sodium-glucose cotransporter 2 inhibitors and the cancer patient: from diabetes to cardioprotection and beyond","volume":"120","author":"Camilli","year":"2025","journal-title":"Basic Res Cardiol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102790_bib4","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: cardiooncology state-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102790_bib5","first-page":"212","article-title":"Lifestyle and pharmacological interventions to prevent anthracycline-related cardiotoxicity in cancer patients","volume":"12","author":"Spadafora","year":"2025","journal-title":"J Cardiovasc Dev Dis"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102790_bib6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102790_bib7","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.jchf.2022.03.006","article-title":"Sodium-glucose Co-Transporter-2 inhibitors and cardiac outcomes among patients treated with anthracyclines","volume":"10","author":"Gongora","year":"2022","journal-title":"JACC Heart Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib8","first-page":"58","article-title":"Use of EMPAgliflozin in the prevention of CARDiotoxicity: the EMPACARD - PILOT trial","volume":"10","author":"Daniele","year":"2024","journal-title":"Cardiooncology"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102790_bib9","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The Association of Sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in anthracycline-treated patients with cancer","volume":"5","author":"Abdel-Qadir","year":"2023","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib10","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jchf.2023.08.026","article-title":"SGLT2 inhibitor use and risk of clinical events in patients with cancer therapy-related cardiac dysfunction","volume":"12","author":"Avula","year":"2024","journal-title":"JACC Heart Fail"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102790_bib11","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","article-title":"SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes","volume":"6","author":"Bhatti","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102790_bib12","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/jgh.16498","article-title":"The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer","volume":"39","author":"Chiang","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jacadv.2026.102790_bib13","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.amjcard.2024.04.032","article-title":"Cardioprotective potential of sodium-glucose Cotransporter-2 inhibitors in patients with cancer treated with anthracyclines: an observational study","volume":"222","author":"Fath","year":"2024","journal-title":"Am J Cardiol"},{"issue":"9","key":"10.1016\/j.jacadv.2026.102790_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0274519","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis","volume":"17","author":"Hendryx","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabet.2023.101500","article-title":"Effects of SGLT2 inhibitors on clinical cancer survival in patients with type 2 diabetes","volume":"50","author":"Huang","year":"2024","journal-title":"Diabetes Metab"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48678-1","article-title":"Sodium-glucose cotransporter-2 inhibitors improve clinical outcomes in patients with type 2 diabetes mellitus undergoing anthracycline-containing chemotherapy: an emulated target trial using nationwide cohort data in South Korea","volume":"13","author":"Hwang","year":"2023","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib17","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13098-024-01354-4","article-title":"Cardiovascular outcomes associated with SGLT2 inhibitor therapy in patients with type 2 diabetes mellitus and cancer: a systematic review and meta-analysis","volume":"16","author":"Kuo","year":"2024","journal-title":"Diabetol Metab Syndr"},{"issue":"8","key":"10.1016\/j.jacadv.2026.102790_bib18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival","volume":"128","author":"Luo","year":"2023","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib19","first-page":"2","article-title":"Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors","volume":"10","author":"Perelman","year":"2024","journal-title":"Cardiooncology"},{"issue":"4","key":"10.1016\/j.jacadv.2026.102790_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1093\/ehjcvp\/pvaf028","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis","volume":"11","author":"Novo","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102790_bib21","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/eurjpc\/zwaf026","article-title":"Impact of sodium-glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis","volume":"33","author":"Bhalraam","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib22","first-page":"50","article-title":"The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis","volume":"11","author":"Reshadmanesh","year":"2025","journal-title":"Cardiooncology"},{"issue":"41","key":"10.1016\/j.jacadv.2026.102790_bib23","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102790_bib24","article-title":"The association between sodium-glucose cotransporter 2 inhibitors treatment and survival in patients with cancer therapy-related cardiac dysfunction","author":"Abbas","year":"2025","journal-title":"Eur J Prev Cardiol"},{"issue":"22","key":"10.1016\/j.jacadv.2026.102790_bib25","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1093\/eurheartj\/ehae161","article-title":"Use of new and emerging cancer drugs: what the cardiologist needs to know","volume":"45","author":"Fabiani","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacadv.2026.102790_bib26","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.125.076616","article-title":"Sacubitril-Valsartan and prevention of cardiac dysfunction during adjuvant breast cancer therapy: the PRADA II randomized clinical trial","author":"Omland","year":"2025","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102790_bib27","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s10741-025-10495-1","article-title":"The SARAH trial: more evidence on the role of neurohormonal blockers in prevention of anthracycline-induced cardiotoxicity","volume":"30","author":"Mecinaj","year":"2025","journal-title":"Heart Fail Rev"},{"issue":"2","key":"10.1016\/j.jacadv.2026.102790_bib28","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","article-title":"The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: cardiooncology state-of-the-art review","volume":"6","author":"Dabour","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12933-021-01346-y","article-title":"The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin","volume":"20","author":"Quagliariello","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102790_bib30","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.jaccao.2025.01.017","article-title":"Balancing promise and evidence: critical perspectives on SGLT2 inhibitors for cardiotoxicity prevention","volume":"7","author":"Karakasis","year":"2025","journal-title":"JACC CardioOncol"},{"issue":"10","key":"10.1016\/j.jacadv.2026.102790_bib31","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s11912-024-01577-8","article-title":"Sodium-glucose cotransporter 2 inhibitors during cancer therapy: benefits, risks, and ongoing clinical trials","volume":"26","author":"Osataphan","year":"2024","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib32","first-page":"79","article-title":"SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +\/- trastuzumab: rationale and design of the multicenter PROTECT trial","volume":"11","author":"Greco","year":"2025","journal-title":"Cardiooncology"},{"issue":"6","key":"10.1016\/j.jacadv.2026.102790_bib33","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10741-019-09820-2","article-title":"Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens","volume":"24","author":"Cadeddu Dessalvi","year":"2019","journal-title":"Heart Fail Rev"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib34","first-page":"86","article-title":"A comprehensive review on the effects of sex hormones on chemotherapy-induced cardiotoxicity: are they lucrative or unprofitable?","volume":"10","author":"Kheradkhah","year":"2024","journal-title":"Cardiooncology"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13293-018-0198-2","article-title":"Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity","volume":"9","author":"Meiners","year":"2018","journal-title":"Biol Sex Differ"},{"issue":"1","key":"10.1016\/j.jacadv.2026.102790_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1751-7133.2009.00118.x","article-title":"Treatment of heart failure in African Americans: a consensus statement","volume":"16","author":"Franciosa","year":"2010","journal-title":"Congest Heart Fail"},{"issue":"5","key":"10.1016\/j.jacadv.2026.102790_bib37","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.jchf.2018.02.015","article-title":"African Americans are less likely to receive care by a cardiologist during an intensive care unit admission for heart failure","volume":"6","author":"Breathett","year":"2018","journal-title":"JACC Heart Fail"},{"issue":"3","key":"10.1016\/j.jacadv.2026.102790_bib38","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.jaccao.2024.02.009","article-title":"Social determinants of health in cardio-oncology: multi-level strategies to overcome disparities in care: JACC: cardiooncology state-of-the-art review","volume":"6","author":"Osei Baah","year":"2024","journal-title":"JACC CardioOncol"},{"issue":"21","key":"10.1016\/j.jacadv.2026.102790_bib39","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1161\/CIR.0000000000000534","article-title":"Cardiovascular health in African Americans: a scientific statement from the American Heart Association","volume":"136","author":"Carnethon","year":"2017","journal-title":"Circulation"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26002115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X26002115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:25:27Z","timestamp":1783725927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X26002115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2772963X26002115"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102790","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SGLT2 Inhibitors in Cardio-Oncology","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2026.102790","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102790"}}